Patients with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) who were alive 2 years after tafamidis initiation had a less advanced disease profile than those who died, according to a recent study published in the European Journal of Heart Failure.
The study’s authors aimed to identify patient- and disease-level characteristics associated with 2-year survival among patients with ATTR-CM receiving tafamidis. Rather than comparing tafamidis with placebo or another therapy, they examined whether routinely collected clinical, biochemical, electrocardiographic, and echocardiographic findings could differentiate patients with better outcomes within a treated registry cohort.
The investigators retrospectively analyzed prospectively collected data from a single-center registry, including 79 consecutive patients who initiated tafamidis between April 1, 2021, and December 31, 2023, with standardized outpatient follow-up every 6 months.